BE880905A - Compositions influencant le systeme nerveux central et leur methode d'utilisation - Google Patents

Compositions influencant le systeme nerveux central et leur methode d'utilisation

Info

Publication number
BE880905A
BE880905A BE0/198784A BE198784A BE880905A BE 880905 A BE880905 A BE 880905A BE 0/198784 A BE0/198784 A BE 0/198784A BE 198784 A BE198784 A BE 198784A BE 880905 A BE880905 A BE 880905A
Authority
BE
Belgium
Prior art keywords
nervous system
central nervous
influencing
compositions
compositions influencing
Prior art date
Application number
BE0/198784A
Other languages
English (en)
Original Assignee
Merz & Cy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Cy filed Critical Merz & Cy
Publication of BE880905A publication Critical patent/BE880905A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE0/198784A 1978-12-27 1979-12-27 Compositions influencant le systeme nerveux central et leur methode d'utilisation BE880905A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2856393A DE2856393C2 (de) 1978-12-27 1978-12-27 Arzneimittel zur Behandlung von Morbus Parkinson

Publications (1)

Publication Number Publication Date
BE880905A true BE880905A (fr) 1980-06-27

Family

ID=6058522

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/198784A BE880905A (fr) 1978-12-27 1979-12-27 Compositions influencant le systeme nerveux central et leur methode d'utilisation

Country Status (10)

Country Link
US (1) US4273774A (fr)
JP (1) JPS5589219A (fr)
BE (1) BE880905A (fr)
CA (1) CA1121726A (fr)
DE (1) DE2856393C2 (fr)
FR (1) FR2445145A1 (fr)
GB (1) GB2044098B (fr)
NL (1) NL7909307A (fr)
SE (1) SE448517B (fr)
SG (1) SG3185G (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33080E (en) * 1981-08-31 1989-10-03 Exxon Research And Engineering Company Adamantane catalyzed paraffin isomerization
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP2260844A1 (fr) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combinaison d'un antagoniste de récepteur NMDA et d'un inhibiteur de la recapture sélective de la sérotonine pour le traitement de la dépression et d'autres troubles de l'humeur
MXPA05012810A (es) * 2003-06-16 2006-02-13 Allergan Inc Formas de dosis oral de memantina.
WO2005079779A1 (fr) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa Utilisation de derives de 1-aminocyclohexane pour modifier le depot de peptides a$g(b) fibrillogenes dans des amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005067908A2 (fr) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine destinee au traitement de la maladie d'alzheimer legere et legere a moderee
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja) 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006034465A1 (fr) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine pour le traitement des troubles du comportement de l'enfant
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
EP1898890A1 (fr) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Formulation de gouttes de memantine a liberation modifiee et immediate
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP2040676A2 (fr) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
WO2008063847A2 (fr) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Méthode de traitement de l'autisme
EP2085398A1 (fr) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
WO2009151498A2 (fr) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Formulations de mémantine
EP2288345B1 (fr) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Produits psycho-pharmaceutiques
EP2111858A1 (fr) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Nouveau traitement pour la maladie d'Alzheimer
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (fr) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CA2994873A1 (fr) 2009-12-02 2011-06-09 Adamas Pharma, Llc Compositions d'amantadine et procedes d'utilisation associes
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
MX2013004760A (es) 2010-10-29 2013-07-02 Merz Pharma Gmbh & Co Kgaa Derivados de indol y proceso para su preparacion.
EP3034079B1 (fr) 2010-11-15 2018-01-10 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
AR084516A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
WO2012152854A1 (fr) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
EP2650284A1 (fr) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
DK2892540T3 (en) * 2012-09-06 2018-11-19 Mcpharma Biotech Inc TREATMENT OF DIARRES AND DRAWN DIARRES WITH RESISTANT POTATO STARCH
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3102186B1 (fr) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Compositions de donépézil et procédé de traitement de la maladie d'alzheimer
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
WO2017223402A1 (fr) 2016-06-23 2017-12-28 Corium International, Inc. Matrice adhésive à un domaine hydrophile, un domaine hydrophobes et un agent thérapeutique
CN116270551A (zh) 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
EP3490544A1 (fr) 2016-07-27 2019-06-05 Corium International, Inc. Systèmes d'administration transdermique de mémantine
WO2018022814A1 (fr) 2016-07-27 2018-02-01 Corium International, Inc. Systèmes d'administration transdermique à pharmacocinétique bioéquivalent à l'administration orale
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN119095622A (zh) 2022-02-08 2024-12-06 菲克雷特·萨欣 Nmdar拮抗剂通过提高20s蛋白酶体活性来预防老化和老化相关病况和疾病
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864489A (en) * 1972-03-20 1975-02-04 Gen Foods Corp Treatment of hyperkinetic conditions with caffeine
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
DE2518677A1 (de) * 1974-05-06 1975-11-20 Sandoz Ag Neue pharmazeutische zubereitungen

Also Published As

Publication number Publication date
US4273774A (en) 1981-06-16
DE2856393C2 (de) 1983-04-28
FR2445145A1 (fr) 1980-07-25
SE448517B (sv) 1987-03-02
SE7910501L (sv) 1980-06-28
FR2445145B1 (fr) 1984-10-26
GB2044098A (en) 1980-10-15
DE2856393A1 (de) 1980-07-03
JPS5589219A (en) 1980-07-05
GB2044098B (en) 1983-01-26
SG3185G (en) 1985-06-14
NL7909307A (nl) 1980-07-01
CA1121726A (fr) 1982-04-13

Similar Documents

Publication Publication Date Title
BE880905A (fr) Compositions influencant le systeme nerveux central et leur methode d'utilisation
MA19845A1 (fr) Nouvelles piperidinamines et leur preparation
FI801521A7 (fi) Foerfarande foer rening av fosforsyra med avseende pao tungmetaller
FR2504931B1 (fr) Ionomeres modifies, leur preparation et leur utilisation
BE896993A (fr) FACTEURS 1,2,3,4 et 5 DE TEICHOMYCINE A2, LEUR PREPARATION ET LEUR UTILISATION
PT76528B (fr) Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
BE866841A (fr) Procede de preparation d'imidazoazines et -diazines substituees et leur utilisation
TR20880A (tr) Akrilonitrilin aritilmasi
BE883978A (fr) Bouclier d'attaque
BE890465A (fr) Prothese d'osselets
BE882010A (fr) Tetrahydrobenzothiazolylimidazolidinones et leur utilisation
BE896668A (fr) Iminoderives substitues du dihydrobenzopyranne et du dihydrobenzothiopyranne et leur preparation.
BE894056A (fr) 2-oxo-azetidines, leur preparation et leur utilisation
BE891585A (fr) 5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation
FR2508188B1 (fr) Compositions photosensibles et leur utilisation
FR2322849A1 (fr) Preparation d'aminals et leur utilisation comme pesticides
BE890376R (fr) Preparation d'acetaldehyde
BE888608A (fr) Esters de steroide-oxazoles, leur preparation et leur utilisation,
FR2529205B1 (fr) Furfurylamides d'acides phenoxyphenoxyalcanoiques et leur utilisation comme herbicides selectifs
BE891393A (fr) Esthers d'hydroxymethylpyrazines substituees leur preparation et leur utilisation therapeutique
DE3361290D1 (de) Preparation of cyanobenzoic-acid esters
BE895664A (fr) Esters d'acides phenoxyphenoxypropioniques leur preparation et leur utilisation
BE895662A (fr) Esters heterocycliques d'acides phenoxybenzoiques, leur preparation et leur utilisation
BE887203A (fr) Isoxazolyl- et isoxazolinyl-prostaglandines et leur preparation
BE876030A (fr) Diesters d'ethylenesglycol, leur preparation et leur utilisation

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: MERZ & CY

Effective date: 19911231